Theme

MONALEESA-3 PRO Analysis

Source
Source: Fasching PA, Beck JT, Chan A, et al. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. The Breast. 2020;54:148-154.

Ribociclib + Fulvestrant: Survival Benefits Without Compromising Quality of Life

Study Architecture

  • Population: 726 postmenopausal women (HR+/HER2- advanced BC). First- or second-line.
  • Investigational (n=484): Ribociclib (600 mg) + Fulvestrant.
  • Control (n=242): Placebo + Fulvestrant.
  • Assessment: EORTC QLQ-C30, BPI-SF, EQ-5D-5L every 8 weeks.
Global Health Status Time to Definitive Deterioration
0.81 HR
95% CI (0.62–1.06)
Trend favors Ribociclib

Time to Deterioration (HR)

Key PRO Outcomes

Quality of Life

Improved PFS translates to longer maintained QoL. No negative impact vs endocrine therapy alone.

Pain Progression

Delayed severe pain deterioration. HR 0.77 trend suggests better symptom control.

Emotional Function

Trend toward prolonged maintenance of emotional functioning (HR 0.76).

Clinical Implication: Combat "Toxicity Anxiety"

While primary data proves survival extension, this PRO data answers the patient's critical question: "How will I feel?"

Recommendation: Emphasize that adding Ribociclib to Fulvestrant provides superior efficacy while maintaining the same Global Health Status and symptom burden as Fulvestrant monotherapy. Use this narrative to maximize adherence and reassure patients initiating therapy.

AbbreviationsQuick
BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire; FUL, fulvestrant; GHS, global health status; HER2-, human epidermal growth factor receptor 2-negative; HR, hazard ratio; HR+, hormone receptor-positive; HRQOL, health-related quality of life; LSM, least squares mean; OS, overall survival; PBO, placebo; PFS, progression-free survival; PRO, patient-reported outcome; RIB, ribociclib; SEM, standard error of the mean; TTD, time to definitive deterioration.
Bibliography1
  1. Fasching PA, Beck JT, Chan A, et al. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. The Breast. 2020;54:148-154. (DOI: 10.1016/j.breast.2020.09.008 | link)